Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397906 | 1.00 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29423575 | 1.00 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL13525077 | 0.95 | KMT2A (0.73) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL3140809 | 0.95 | KMT2A (0.73) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29792075 | 0.92 | KMT2A (0.90) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29370234 | 0.92 | KMT2A (0.90) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL178801 | 0.92 | KMT2A (0.90) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL18429473 | 0.91 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29587296 | 0.91 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP5FABP7 | |
| Water SCHEMBL21809392 | 0.91 | KMT2A (0.88) | KMT2AEPHX2CASP3FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 715 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874813-A | Short peptide compound and preparation method thereof, cosmetic composition and application | 常州市智态生创科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119859167-A | Preparation method of ISARIDIN E cyclic ester peptide | 中山大学 | 2025-04-22 | — | — | CN | claimed |
| CN-119529014-A | Tripterine-platinum (IV) complex with antitumor activity and preparation method and application thereof | 河北大学 | 2025-02-28 | — | — | CN | claimed |
| CN-115521362-B | Preparation method of Pseudodestruxin B | 哈尔滨工业大学（深圳） | 2024-05-28 | — | — | CN | claimed |
| CN-117285592-A | Preparation method of cyclohexalipopeptides natural product Cladoamide B | 哈尔滨工业大学（深圳） | 2023-12-26 | — | — | CN | claimed |
| CN-117285602-A | Preparation method of depsipeptide natural product Isaridin A | 哈尔滨工业大学（深圳） | 2023-12-26 | — | — | CN | claimed |
| CN-115626951-A | CladoamideA preparation method | 哈尔滨工业大学（深圳） | 2023-01-20 | — | — | CN | claimed |
| CN-115521358-A | Preparation method of destruxins B | 哈尔滨工业大学（深圳） | 2022-12-27 | — | — | CN | claimed |
| CN-115521362-A | Preparation method of pseudodestruxinB | 哈尔滨工业大学（深圳） | 2022-12-27 | — | — | CN | claimed |
| CN-112694429-B | Polypeptide and application thereof in preparing ACE inhibitor or blood pressure lowering product | 江苏医药职业学院 | 2022-08-19 | — | — | CN | claimed |
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| CN-113999141-A | Synthesis method of N-Fmoc-3-aminopropionic acid derivative | 苏州爱玛特生物科技有限公司 | 2022-02-01 | — | — | CN | claimed |
| CN-112694429-A | Polypeptide and application thereof in preparing ACE inhibitor or blood pressure lowering product | 江苏医药职业学院 | 2021-04-23 | — | — | CN | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-111747967-A | Dihydroartemisinin/neurotransmitter split compound and its synthesis method and use | 广州药本君安医药科技股份有限公司 | 2020-10-09 | — | — | CN | claimed |
| EP-0357750-B1 | URETHANE-PROTECTED AMINO ACID-N-CARBOXYANHYDRIDES | BIORESEARCH INC (US) | 1994-07-13 | — | — | EP | claimed |
| US-20260139075-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | ROCHE DIAGNOSTICS OPERATIONS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-1989009625-A1 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING | COCKBAIN, JULIAN, RODERICK, MICHAELSON (GB) | 1989-10-19 | — | — | WO | disclosed |
| EP-0312360-A2 | 25-Hydroxy vitamin D3 derivatives | TOYO JOZO KABUSHIKI KAISHA (JP) | 1989-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139075-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | CD22, LY96, F13B | KMT2A 1552/4885EPHX2 2192/4885CASP3 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.